Denali Therapeutics Inc.

DNLINASDAQHealthcareBiotechnology

$18.34- (-)1Y +9.69%

As of Oct 15, 2026 close

Market cap: $3.44B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $13.75$27.30
Volume (live): -
Avg. volume (3M): 1.81M

Denali Therapeutics Inc. (DNLI) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Denali Therapeutics Inc. stock.

Analyst Consensus Rating

Investment consensus from 12 professional research analysts

Consensus Rating

Buy

Based on 12 unique analysts

(13 total ratings in last 90 days)

High Confidence10.0:1 Buy/Sell

Average Price Target

$36.11

+96.89% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest DNLI Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Aug 25, 2026	Mayank Mamtani	B Riley	Maintains	Buy	$30.00 → $35.00 +5.00 (+16.7%)
Aug 20, 2026	Ekta Bagri	Zacks Equity Research	Initiates Coverage	Hold	-
Aug 11, 2026	Jessica Fye	JP Morgan	Maintains	Buy	$29.00
Aug 7, 2026	Paul Matteis	Stifel Nicolaus	Reiterates	Buy	$41.00
Aug 7, 2026	Andrew Fein	HC Wainwright	Maintains	Buy	$42.00
Aug 7, 2026	Thomas Shrader	BTIG	Maintains	Buy	$39.00
Aug 7, 2026	Tazeen Ahmad	BofA Securities	Reiterates	Buy	$31.00
Aug 7, 2026	Michael Yee	UBS	Reiterates	Buy	$25.00 → $34.00 +9.00 (+36.0%)
Aug 7, 2026	Charles Moore	Baird	Maintains	Buy	$31.00 → $34.00 +3.00 (+9.7%)
Aug 7, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Sell	-
Aug 7, 2026	Sean Laaman	Morgan Stanley	Reiterates	Buy	$36.00 → $40.00 +4.00 (+11.1%)
Aug 6, 2026	Thomas Shrader	BTIG	Maintains	Buy	$39.00
Aug 6, 2026	Joseph Thome	TD Cowen	Maintains	Buy	-

Mayank Mamtani

B Riley

BuyMaintains

$30.00 → $35.00

Aug 25

Ekta Bagri

Zacks Equity Research

HoldInitiates Coverage

Aug 20

Jessica Fye

JP Morgan

BuyMaintains

$29.00

Aug 11

Paul Matteis

Stifel Nicolaus

BuyReiterates

$41.00

Aug 7

Andrew Fein

HC Wainwright

BuyMaintains

$42.00

Aug 7

Thomas Shrader

BTIG

BuyMaintains

$39.00

Aug 7

Tazeen Ahmad

BofA Securities

BuyReiterates

$31.00

Aug 7

Michael Yee

UBS

BuyReiterates

$25.00 → $34.00

Aug 7

Charles Moore

Baird

BuyMaintains

$31.00 → $34.00

Aug 7

Zacks Equity Research

SellInitiates Coverage

Aug 7

Sean Laaman

Morgan Stanley

BuyReiterates

$36.00 → $40.00

Aug 7

Thomas Shrader

BTIG

BuyMaintains

$39.00

Aug 6

Joseph Thome

TD Cowen

BuyMaintains

Aug 6

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Aug 25, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for DNLI?

The analyst consensus rating for DNLI is Buy, based on the latest ratings from 12 analysts over the last 90 days.

What is the average price target for DNLI?

The average 12-month price target for DNLI is $36.11, representing an upside of 96.9% from the Oct 15, 2026 close of $18.34.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.